{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:46:35Z","timestamp":1785750395025,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U34AR068616"],"award-info":[{"award-number":["U34AR068616"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R61NS119639"],"award-info":[{"award-number":["R61NS119639"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R21TR004895; R44NS095423; 5U54HD090254;"],"award-info":[{"award-number":["R21TR004895; R44NS095423; 5U54HD090254;"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"crossref","award":["667078"],"award-info":[{"award-number":["667078"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-61162-w","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:04:26Z","timestamp":1785747866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prednisone, not vamorolone, suppresses novel serum bone and cartilage biomarkers associated with growth failure in children with Duchenne muscular dystrophy"],"prefix":"10.1038","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03439670","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rebecca A.","family":"Tobin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh J.","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hagerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Rooman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Heinz","family":"Konopka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Damsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ziemba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetrib","family":"Hathout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"61162_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0049-0172(00)80011-6","volume":"29","author":"JD Adachi","year":"2000","unstructured":"Adachi, J. D. et al. Management of corticosteroid-induced osteoporosis. Semin. Arthritis Rheum. 29, 228\u2013251 (2000).","journal-title":"Semin. Arthritis Rheum."},{"key":"61162_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/OARRR.S282606","volume":"13","author":"AO Kobza","year":"2021","unstructured":"Kobza, A. O., Herman, D., Papaioannou, A., Lau, A. N. & Adachi, J. D. Understanding and managing corticosteroid-induced osteoporosis. Open Access Rheumatol. 13, 177\u2013190 (2021).","journal-title":"Open Access Rheumatol."},{"key":"61162_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1210\/endrev\/bnad016","volume":"44","author":"R Pofi","year":"2023","unstructured":"Pofi, R., Caratti, G., Ray, D. W. & Tomlinson, J. W. Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad?. Endocr. Rev. 44, 975\u20131011 (2023).","journal-title":"Endocr. Rev."},{"key":"61162_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13023-021-02158-9","volume":"17","author":"G Stimpson","year":"2022","unstructured":"Stimpson, G. et al. Growth pattern trajectories in boys with Duchenne muscular dystrophy. Orphanet J. Rare Dis. 17, 20 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"61162_CR5","unstructured":"Williams, C., Anastasopoulou, C., Sapra, A. Biochemical Markers of Osteoporosis. 2024 Nov 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025."},{"key":"61162_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1164\/rccm.2110047","volume":"166","author":"LJ Walsh","year":"2022","unstructured":"Walsh, L. J. et al. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am. J. Respir. Crit. Care Med. 166, 691\u2013695 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"61162_CR7","first-page":"RC04","volume":"9","author":"S Singh","year":"2015","unstructured":"Singh, S., Kumar, D. & Lal, A. K. Serum osteocalcin as a diagnostic biomarker for primary osteoporosis in women. J. Clin. Diagn. Res. 9, RC04-7 (2015).","journal-title":"J. Clin. Diagn. Res."},{"key":"61162_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24656","volume":"36","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Broad application prospects of bone turnover markers in pediatrics. J. Clin. Lab. Anal. 36, e24656 (2022).","journal-title":"J. Clin. Lab. Anal."},{"key":"61162_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12891-016-1135-3","volume":"17","author":"DL Fleishaker","year":"2016","unstructured":"Fleishaker, D. L., Mukherjee, A., Whaley, F. S., Daniel, S. & Zeiher, B. G. Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study. BMC. Musculoskelet. Disord. 17, 293 (2016).","journal-title":"BMC. Musculoskelet. Disord."},{"key":"61162_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/rheumatology\/37.1.27","volume":"37","author":"WF Lems","year":"1998","unstructured":"Lems, W. F. et al. Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br. J. Rheumatol. 37, 27\u201333 (1998).","journal-title":"Br. J. Rheumatol."},{"key":"61162_CR11","first-page":"105","volume":"4","author":"HK Nielsen","year":"1988","unstructured":"Nielsen, H. K. et al. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner. 4, 105\u2013113 (1988).","journal-title":"Bone Miner."},{"key":"61162_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","volume":"79","author":"M Guglieri","year":"2022","unstructured":"Guglieri, M. et al. Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: A randomized clinical trial. JAMA. Neurol. 79, 1005\u20131014 (2022).","journal-title":"JAMA. Neurol."},{"key":"61162_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1210\/jc.2018-01083","volume":"104","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. Impact of vertebral fractures and glucocorticoid exposure on height deficits in children during treatment of leukemia. J. Clin. Endocrinol. Metab. 104, 213\u2013222 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"61162_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000624","volume":"9","author":"O Steg Saban","year":"2025","unstructured":"Steg Saban, O. et al. Children with autoimmune hepatitis receiving standard-of-care therapy demonstrate long-term obesity and linear growth delay. Hepatol. Commun. 9, e0624 (2025).","journal-title":"Hepatol. Commun."},{"key":"61162_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12891-024-08247-7","volume":"26","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Risk factors for growth retardation in children with juvenile idiopathic arthritis: a case-control study. BMC Musculoskelet. Disord. 26, 85 (2025).","journal-title":"BMC Musculoskelet. Disord."},{"key":"61162_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","volume":"134","author":"EP Hoffman","year":"2018","unstructured":"Hoffman, E. P. et al. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134, 43\u201352 (2018).","journal-title":"Steroids"},{"key":"61162_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","volume":"136","author":"LS Conklin","year":"2018","unstructured":"Conklin, L. S. et al. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol. Res. 136, 140\u2013150 (2018).","journal-title":"Pharmacol. Res."},{"key":"61162_CR18","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","volume":"93","author":"EP Hoffman","year":"2019","unstructured":"Hoffman, E. P. et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology 93, e1312\u2013e1323 (2019).","journal-title":"Neurology"},{"key":"61162_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208112","volume":"102","author":"UJ Dang","year":"2024","unstructured":"Dang, U. J. et al. Efficacy and safety of vamorolone over 48 weeks in boys with duchenne muscular dystrophy: a randomized controlled trial. Neurology 102, e208112 (2024).","journal-title":"Neurology"},{"key":"61162_CR20","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1093\/rheumatology\/keaf129","volume":"64","author":"A Crastin","year":"2025","unstructured":"Crastin, A. et al. Vamorolone: A Novel Metabolism Resistant Steroid that Suppresses Joint Destruction in Chronic Polyarthritis with Reduced Systemic Side Effects. Rheumatology [Oxford]. 64, 4371\u20134381 (2025).","journal-title":"Rheumatology [Oxford]."},{"key":"61162_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00011-019-01279-z","volume":"68","author":"JM Damsker","year":"2019","unstructured":"Damsker, J. M. et al. Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset. Inflamm. Res. 68, 969\u2013980 (2019).","journal-title":"Inflamm. Res."},{"key":"61162_CR22","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/emmm.201302621","volume":"5","author":"CR Heier","year":"2013","unstructured":"Heier, C. R. et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol. Med. 5, 1569\u20131585 (2013).","journal-title":"EMBO Mol. Med."},{"key":"61162_CR23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","volume":"327","author":"M Guglieri","year":"2022","unstructured":"Guglieri, M. et al. Effect of different corticosteroid dosing regimens on clinical outcomes in boys with duchenne muscular dystrophy: A randomized clinical trial. JAMA 327, 1456\u20131468 (2022).","journal-title":"JAMA"},{"key":"61162_CR24","doi-asserted-by":"publisher","first-page":"24285","DOI":"10.1073\/pnas.2006890117","volume":"117","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. USA 117, 24285\u201324293 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61162_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2025.109689","volume":"223","author":"A de Vera","year":"2025","unstructured":"de Vera, A. et al. Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials. Steroids 223, 109689 (2025).","journal-title":"Steroids"},{"key":"61162_CR26","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201800186","volume":"2","author":"CR Heier","year":"2019","unstructured":"Heier, C. R. et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci. Alliance. 2, e201800186 (2019).","journal-title":"Life Sci. Alliance."},{"key":"61162_CR27","doi-asserted-by":"publisher","first-page":"39997","DOI":"10.1038\/s41598-025-23758-6","volume":"15","author":"F Ahmadiharchegani","year":"2025","unstructured":"Ahmadiharchegani, F. et al. Circulating protein biomarkers identified in two independent clinical trial cohorts of glucocorticoid-naive Duchenne muscular dystrophy patients. Sci. Rep. 15, 39997 (2025).","journal-title":"Sci. Rep."},{"key":"61162_CR28","doi-asserted-by":"publisher","first-page":"26504","DOI":"10.1021\/acsomega.0c03206","volume":"5","author":"TD Alayi","year":"2020","unstructured":"Alayi, T. D. et al. Tandem mass tag-based serum proteome profiling for biomarker discovery in young Duchenne muscular dystrophy boys. ACS Omega 5, 26504\u201326517 (2020).","journal-title":"ACS Omega"},{"key":"61162_CR29","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/hmg\/ddaa132","volume":"29","author":"UJ Dang","year":"2020","unstructured":"Dang, U. J. Serum biomarkers associated with baseline clinical severity in young steroid-na\u00efve Duchenne muscular dystrophy boys. Hum. Mol. Genet. 29, 2481\u20132495 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"61162_CR30","doi-asserted-by":"publisher","first-page":"12167","DOI":"10.1038\/s41598-019-48548-9","volume":"9","author":"Y Hathout","year":"2019","unstructured":"Hathout, Y. et al. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy. Sci. Rep. 9, 12167 (2019).","journal-title":"Sci. Rep."},{"key":"61162_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/jcsm.12304","volume":"9","author":"P Spitali","year":"2018","unstructured":"Spitali, P. et al. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. J. Cachexia Sarcopenia Muscle. 9, 715\u2013726 (2018).","journal-title":"J. Cachexia Sarcopenia Muscle."},{"key":"61162_CR32","doi-asserted-by":"publisher","first-page":"835720","DOI":"10.3389\/fendo.2022.835720","volume":"13","author":"M Gado","year":"2022","unstructured":"Gado, M., Baschant, U., Hofbauer, L. C. & Henneicke, H. Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes. Front. Endocrinol. Lausanne. 13, 835720 (2022).","journal-title":"Front. Endocrinol. Lausanne."},{"key":"61162_CR33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1055\/s-0040-1718573","volume":"39","author":"EV Asztalos","year":"2022","unstructured":"Asztalos, E. V., Murphy, K. E. & Matthews, S. G. A Growing Dilemma: Antenatal Corticosteroids and Long-Term Consequences. Am. J. Perinatol. 39, 592\u2013600 (2022).","journal-title":"Am. J. Perinatol."},{"key":"61162_CR34","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello, L. et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology 85, 1048\u20131055 (2015).","journal-title":"Neurology"},{"key":"61162_CR35","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1210\/clinem\/dgab084","volume":"106","author":"L Plachy","year":"2021","unstructured":"Plachy, L. et al. Familial short stature-a novel phenotype of growth plate collagenopathies. J. Clin. Endocrinol. Metab. 106, 1742\u20131749 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"61162_CR36","doi-asserted-by":"publisher","first-page":"eaan4669","DOI":"10.1126\/scitranslmed.aan4669","volume":"9","author":"RF Coghlan","year":"2017","unstructured":"Coghlan, R. F. et al. A degradation fragment of type X collagen is a real-time marker for bone growth velocity. Sci. Transl. Med. 9, eaan4669 (2017).","journal-title":"Sci. Transl. Med."},{"key":"61162_CR37","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMoa2411790","volume":"392","author":"R Savarirayan","year":"2025","unstructured":"Savarirayan, R. et al. Oral infigratinib therapy in children with achondroplasia. N. Engl. J. Med. 392, 865\u2013874 (2025).","journal-title":"N. Engl. J. Med."},{"key":"61162_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","volume":"396","author":"R Savarirayan","year":"2020","unstructured":"Savarirayan, R. et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet 396, 684\u2013692 (2020).","journal-title":"Lancet"},{"key":"61162_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44178","volume":"5","author":"JK Mah","year":"2022","unstructured":"Mah, J. K. et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: A 30-month nonrandomized controlled open-label extension trial. JAMA Netw. Open. 5, e2144178 (2022).","journal-title":"JAMA Netw. Open."},{"key":"61162_CR40","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.62347\/JWGW7377","volume":"14","author":"T Han","year":"2024","unstructured":"Han, T. et al. Collagen type X expression and chondrocyte hypertrophic differentiation during OA and OS development. Am. J. Cancer Res. 14, 1784\u20131801 (2024).","journal-title":"Am. J. Cancer Res."},{"key":"61162_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116634","volume":"167","author":"A Schulz","year":"2023","unstructured":"Schulz, A. & Moshous, D. Hematopoietic stem cell transplantation, a curative approach in infantile osteopetrosis. Bone 167, 116634 (2023).","journal-title":"Bone"},{"key":"61162_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310824","volume":"24","author":"L Alcaide-Ruggiero","year":"2023","unstructured":"Alcaide-Ruggiero, L., Cugat, R. & Dom\u00ednguez, J. M. Proteoglycans in articular cartilage and their contribution to chondral injury and repair mechanisms. Int. J. Mol. Sci. 24, 10824 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"61162_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/BOR.0000000000000845","volume":"34","author":"AC Bay-Jensen","year":"2022","unstructured":"Bay-Jensen, A. C., Mobasheri, A., Thudium, C. S., Kraus, V. B. & Karsdal, M. A. Blood and urine biomarkers in osteoarthritis - an update on cartilage associated type II collagen and aggrecan markers. Curr. Opin. Rheumatol. 34, 54\u201360 (2022).","journal-title":"Curr. Opin. Rheumatol."},{"key":"61162_CR44","doi-asserted-by":"publisher","first-page":"10371","DOI":"10.1038\/s41598-021-89653-y","volume":"11","author":"KC K\u00f6nig","year":"2021","unstructured":"K\u00f6nig, K. C. et al. Aggrecan: a new biomarker for acute type A aortic dissection. Sci Rep. 11, 10371 (2021).","journal-title":"Sci Rep."},{"key":"61162_CR45","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1007\/s11010-021-04216-z","volume":"476","author":"S Appunni","year":"2021","unstructured":"Appunni, S. et al. Biglycan: An emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance. Mol. Cell. Biochem. 476, 3935\u20133950 (2021).","journal-title":"Mol. Cell. Biochem."},{"key":"61162_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/nep.13832","volume":"26","author":"J Aoyagi","year":"2021","unstructured":"Aoyagi, J. et al. Glucocorticoid effects on bone strength in children with renal diseases. Nephrology 26, 119\u2013125 (2021).","journal-title":"Nephrology"},{"key":"61162_CR47","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/nep.14382","volume":"29","author":"J Aoyagi","year":"2024","unstructured":"Aoyagi, J. et al. Trends of bone mineral density and bone quality in a paediatric kidney transplant recipient: A case report. Nephrology (Carlton). 29, 955\u2013959 (2024).","journal-title":"Nephrology (Carlton)."},{"key":"61162_CR48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2265.1996.706cn527.x","volume":"44","author":"PM Crofton","year":"1996","unstructured":"Crofton, P. M., Stirling, H. F., Sch\u00f6nau, E. & Kelnar, C. J. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. Clin. Endocrinol. (Oxf) 44, 385\u2013394 (1996).","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"61162_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S8756-3282(99)00245-8","volume":"26","author":"G Silvestrini","year":"2000","unstructured":"Silvestrini, G. et al. Evaluation of apoptosis and the glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-dose treatment with corticosterone. Bone 26, 33\u201342 (2000).","journal-title":"Bone"},{"key":"61162_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22734-8","volume":"12","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. TNF overexpression and dexamethasone treatment impair chondrogenesis and bone growth in an additive manner. Sci. Rep. 12, 18189 (2022).","journal-title":"Sci. Rep."},{"key":"61162_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41413-024-00342-8","volume":"12","author":"L Hu","year":"2024","unstructured":"Hu, L., Chen, W., Qian, A. & Li, Y. P. Wnt\/\u03b2-catenin signaling components and mechanisms in bone formation, homeostasis, and disease. Bone Res. 12, 39 (2024).","journal-title":"Bone Res."},{"key":"61162_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2026.106414","volume":"62","author":"M Guridi","year":"2026","unstructured":"Guridi, M. et al. Assessing biomarkers of bone metabolism and the role of the interleukin-6 signaling pathway in patients with Duchenne muscular dystrophy. Neuromuscul. Disord. 62, 106414 (2026).","journal-title":"Neuromuscul. Disord."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61162-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61162-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61162-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:04:28Z","timestamp":1785747868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61162-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61162"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61162-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LH, JD, and EPH are employed and own stock in ReveraGen BioPharma. RR and KHK are employees of Santhera Pharmaceuticals.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval\/clearance was received for the VBP15-004 clinical trial at each participating academic clinical center, and informed consent (parents) and assent (children) as required by each center.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"21839"}}